Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 80

1.

Evaluation of HIV-1 reservoir levels as possible markers for virological failure during boosted darunavir monotherapy.

Rutsaert S, De Spiegelaere W, De Clercq L, Vandekerckhove L.

J Antimicrob Chemother. 2019 Jul 17. pii: dkz269. doi: 10.1093/jac/dkz269. [Epub ahead of print]

PMID:
31314108
2.
3.

Early treated HIV-1 positive individuals demonstrate similar restriction factor expression profile as long-term non-progressors.

Van Hecke C, Trypsteen W, Malatinkova E, De Spiegelaere W, Vervisch K, Rutsaert S, Kinloch-de Loes S, Sips M, Vandekerckhove L.

EBioMedicine. 2019 Mar;41:443-454. doi: 10.1016/j.ebiom.2019.02.006. Epub 2019 Feb 12. No abstract available.

4.

In-vitro viral suppressive capacity correlates with immune checkpoint marker expression on peripheral CD8+ T cells in treated HIV-positive patients.

Pannus P, Adams P, Willems E, Heyndrickx L, Florence E, Rutsaert S, De Spiegelaere W, Vandekerckhove L, Seguin-Devaux C, Vanham G.

AIDS. 2019 Mar 1;33(3):387-398. doi: 10.1097/QAD.0000000000002068.

PMID:
30702513
5.

Switching from a protease inhibitor-based regimen to a dolutegravir-based regimen: a randomized clinical trial to determine the effect on peripheral blood and ileum biopsies from ART-suppressed HIV-infected individuals.

Moron-Lopez S, Navarro J, Jimenez M, Rutsaert S, Urrea V, Puertas MC, Torrella A, Clercq L, Ribas BP, Gálvez C, Salgado M, Vandekerckhove L, Blanco J, Crespo M, Martinez-Picado J.

Clin Infect Dis. 2018 Dec 24. doi: 10.1093/cid/ciy1095. [Epub ahead of print]

PMID:
30590412
6.

Increased levels of systemic LPS-positive bacterial extracellular vesicles in patients with intestinal barrier dysfunction.

Tulkens J, Vergauwen G, Van Deun J, Geeurickx E, Dhondt B, Lippens L, De Scheerder MA, Miinalainen I, Rappu P, De Geest BG, Vandecasteele K, Laukens D, Vandekerckhove L, Denys H, Vandesompele J, De Wever O, Hendrix A.

Gut. 2018 Dec 5. pii: gutjnl-2018-317726. doi: 10.1136/gutjnl-2018-317726. [Epub ahead of print] No abstract available.

7.

In-depth validation of total HIV-1 DNA assays for quantification of various HIV-1 subtypes.

Rutsaert S, De Spiegelaere W, Van Hecke C, De Scheerder MA, Kiselinova M, Vervisch K, Trypsteen W, Vandekerckhove L.

Sci Rep. 2018 Nov 22;8(1):17274. doi: 10.1038/s41598-018-35403-6.

8.

Predictors of virological failure in HIV-1-infected patients switching to dolutegravir maintenance monotherapy.

Wijting I, Rutsaert SL, Rokx C, Burger DM, Verbon A, van Kampen J, Boucher C, Rijnders B, Vandekerckhove L.

HIV Med. 2019 Jan;20(1):63-68. doi: 10.1111/hiv.12675. Epub 2018 Sep 30.

9.

Evaluation of bisulfite kits for DNA methylation profiling in terms of DNA fragmentation and DNA recovery using digital PCR.

Kint S, De Spiegelaere W, De Kesel J, Vandekerckhove L, Van Criekinge W.

PLoS One. 2018 Jun 14;13(6):e0199091. doi: 10.1371/journal.pone.0199091. eCollection 2018.

10.

Long-term use of darunavir/ritonavir-containing regimens in daily practice in Belgium: retrospective observational cohort data of 1701 HIV-patients.

De Wit S, Florence E, Vandekerckhove L, Vandercam B, Goffard JC, Van Wijngaerden E, Moutschen M, Demeester R, Thilakarathne P, Piryns H; BREACH* Consortium.

Acta Clin Belg. 2018 Oct;73(5):341-347. doi: 10.1080/17843286.2018.1458428. Epub 2018 Apr 6.

11.

Highlights from the HIV Cure and Reservoir Symposium, 11-12 September 2017, Ghent, Belgium.

Kint S, Van Hecke C, Cole B, Vandekerckhove L, Sips M.

J Virus Erad. 2018 Jan 1;4(1):55-58.

12.

Digital PCR as a tool to measure HIV persistence.

Rutsaert S, Bosman K, Trypsteen W, Nijhuis M, Vandekerckhove L.

Retrovirology. 2018 Jan 30;15(1):16. doi: 10.1186/s12977-018-0399-0. Review.

13.

Which HIV-infected adults with high CD4 T-cell counts benefit most from immediate initiation of antiretroviral therapy? A post-hoc subgroup analysis of the START trial.

Molina JM, Grund B, Gordin F, Williams I, Schechter M, Losso M, Law M, Ekong E, Mwelase N, Skoutelis A, Wiselka MJ, Vandekerckhove L, Benfield T, Munroe D, Lundgren JD, Neaton JD; INSIGHT START study group.

Lancet HIV. 2018 Apr;5(4):e172-e180. doi: 10.1016/S2352-3018(18)30003-1. Epub 2018 Jan 16.

PMID:
29352723
14.

Impact of the HIV-1 genetic background and HIV-1 population size on the evolution of raltegravir resistance.

Fun A, Leitner T, Vandekerckhove L, Däumer M, Thielen A, Buchholz B, Hoepelman AIM, Gisolf EH, Schipper PJ, Wensing AMJ, Nijhuis M.

Retrovirology. 2018 Jan 5;15(1):1. doi: 10.1186/s12977-017-0384-z.

15.

Abacavir usage patterns and hypersensitivity reactions in the EuroSIDA cohort.

Roen A, Laut K, Pelchen-Matthews A, Borodulina E, Caldeira L, Clarke A, Clotet B, d'Arminio Monforte A, Fätkenheuer G, Gatell Artigas JM, Karpov I, Kuznetsova A, Kyselyova G, Mozer-Lisewska I, Mulcahy F, Ragone L, Scherrer A, Uzdaviniene V, Vandekerckhove L, Vannappagari V, Ostergaard L, Mocroft A; EuroSIDA study.

HIV Med. 2018 Apr;19(4):252-260. doi: 10.1111/hiv.12573. Epub 2017 Dec 22.

PMID:
29271606
16.

Where is the greatest impact of uncontrolled HIV infection on AIDS and non-AIDS events in HIV?

Mocroft A, Laut K, Reiss P, Gatell J, Ormaasen V, Cavassini M, Hadziosmanovic V, Mansinho K, Pradier C, Vasylyev M, Mitsura V, Vandekerckhove L, Ostergaard L, Clarke A, Degen O, Mulcahy F, Castagna A, Sthoeger Z, Flamholc L, Sedláček D, Mozer-Lisewska I, Lundgren JD; EuroSIDA Study.

AIDS. 2018 Jan 14;32(2):205-215. doi: 10.1097/QAD.0000000000001684.

PMID:
29112060
17.

Raltegravir 1200 mg once daily versus raltegravir 400 mg twice daily, with tenofovir disoproxil fumarate and emtricitabine, for previously untreated HIV-1 infection: a randomised, double-blind, parallel-group, phase 3, non-inferiority trial.

Cahn P, Kaplan R, Sax PE, Squires K, Molina JM, Avihingsanon A, Ratanasuwan W, Rojas E, Rassool M, Bloch M, Vandekerckhove L, Ruane P, Yazdanpanah Y, Katlama C, Xu X, Rodgers A, East L, Wenning L, Rawlins S, Homony B, Sklar P, Nguyen BY, Leavitt R, Teppler H; ONCEMRK Study Group.

Lancet HIV. 2017 Nov;4(11):e486-e494. doi: 10.1016/S2352-3018(17)30128-5. Epub 2017 Sep 11.

PMID:
28918877
18.

Fight fire with fire: Gene therapy strategies to cure HIV.

Huyghe J, Magdalena S, Vandekerckhove L.

Expert Rev Anti Infect Ther. 2017 Aug;15(8):747-758. doi: 10.1080/14787210.2017.1353911. Epub 2017 Jul 14. Review.

PMID:
28692305
19.

Highlights from the 24th Conference on Retroviruses and Opportunistic Infections: 13-16 February 2017, Seattle, Washington, USA.

Crowell TA, Lyall H, Malatinkova E, Bhagani S, Hsu D, Colby DJ, Polyak C, Psomas C, Hill A, Gathogo EN, Trypsteen W, Vandekerckhove L, Kinloch S.

J Virus Erad. 2017 Apr 1;3(2):101-108.

20.

Erratum to: HIV integration sites in latently infected cell lines: evidence of ongoing replication.

Symons J, Chopra A, Malatinkova E, De Spiegelaere W, Leary S, Cooper D, Abana CO, Rhodes A, Rezaei SD, Vandekerckhove L, Mallal S, Lewin SR, Cameron PU.

Retrovirology. 2017 Mar 27;14(1):23. doi: 10.1186/s12977-017-0340-y. No abstract available.

Supplemental Content

Loading ...
Support Center